E Fund Management Co. Ltd. Increases Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

E Fund Management Co. Ltd. grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 11.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 11,848 shares of the company’s stock after buying an additional 1,249 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Dyne Therapeutics were worth $279,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at about $34,000. Point72 DIFC Ltd purchased a new position in shares of Dyne Therapeutics in the third quarter worth approximately $36,000. US Bancorp DE boosted its holdings in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the last quarter. KBC Group NV boosted its holdings in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after buying an additional 751 shares during the last quarter. Finally, Quest Partners LLC boosted its holdings in shares of Dyne Therapeutics by 898.3% in the third quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock worth $123,000 after buying an additional 3,090 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,387 shares of company stock worth $142,789 over the last quarter. Insiders own 20.77% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Scotiabank assumed coverage on shares of Dyne Therapeutics in a report on Friday. They issued a “sector outperform” rating and a $50.00 price objective on the stock. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.75.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $12.40 on Friday. The stock has a market cap of $1.40 billion, a P/E ratio of -3.48 and a beta of 1.11. Dyne Therapeutics, Inc. has a 1 year low of $11.62 and a 1 year high of $47.45. The firm’s 50 day moving average price is $15.80 and its 200-day moving average price is $26.45.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.